Skip to content
Screener

Cumberland Pharmaceuticals CPIX Q1 2025 earnings

Reported May 6, 2025 · After market close

Revenue$11.7M
EPS$0.16

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$8.5M
EPS estimate-$0.13

Financials

Q1 2025

Income statement

See full
Revenue$11.7M+37.8%
Gross profit$10.3M+48.6%
Operating income$1.3M+169%
Net income$1.3M+165%
EPS (diluted)$0.08+157%

Balance sheet

See full
Cash & equivalents$15.1M-18.5%
Total debt$5.2M-6.5%
Total equity$28.7M+4.2%
Total assets$69.9M-14.2%

Cash flow

See full
Operating cash flow$3.9M+282%
CapEx$47.6K+14.4%
Free cash flow$3.9M+277%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$59.09M+149%
Enterprise value$49.18M+360%
P/S1.4×+0.8×

Profitability

See full
Gross margin84.3%+0.8pp
Operating margin-8%-3.2pp
Net margin-8%-3.1pp

Returns & leverage

See full
Return on equity-11.7%-4.2pp
Debt / equity0.2×0.0×
Current ratio1.2×-0.1×

Segments

By product

See full
Other revenue$3.1M+1,041%
Vibativ$3.0M+86.9%
Sancuso$2.3M+23.4%

By geography

See full
Non-US$1.2M+81.5%

FAQ

When did Cumberland Pharmaceuticals report Q1 2025 earnings?
Cumberland Pharmaceuticals (CPIX) reported Q1 2025 earnings on May 6, 2025 after market close.
What were Cumberland Pharmaceuticals's Q1 2025 revenue and EPS?
Cumberland Pharmaceuticals reported revenue of $11.7M and eps of $0.16 for Q1 2025.
How did Cumberland Pharmaceuticals's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 37.8% from $8.5M a year earlier.
Where can I find Cumberland Pharmaceuticals's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-022753) and the 10-Q periodic report (0001628280-25-024342) directly on SEC EDGAR. The filing index links above go to sec.gov.